Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination of seven drugs**, none of which are known to be co-formulated under a unique brand or generic name. Each active ingredient is a well-established pharmaceutical agent with different mechanisms of action, primarily used individually: - **Caffeine**: a central nervous system stimulant. - **Efavirenz**: a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as an antiretroviral for HIV infection. - **Losartan**: an angiotensin II receptor blocker (ARB) used for hypertension and cardiovascular risks. - **Omeprazole**: a proton pump inhibitor (PPI) for gastric acid-related disorders. - **Metoprolol**: a beta-1 selective adrenergic receptor blocker for hypertension, angina, and heart failure. - **Chlorzoxazone**: a centrally acting muscle relaxant used for acute musculoskeletal pain and spasm[1][2][3][4][5][6][7]. - **Midazolam**: a benzodiazepine used for sedation, anesthesia, and seizure control. These seven drugs exert effects on diverse biological targets and are typically not used together outside of drug-drug interaction studies or specialized clinical protocols due to complex interactions and contraindications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caffeine + efavirenz + losartan + omeprazole + metoprolol + chlorzoxazone + midazolam.